Robert M Fauve is a notable inventor based in Sèvres, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of glycosyl phospholipid derivatives of nucleosides. With a total of 6 patents to his name, Fauve's work has had a considerable impact on medical research and drug development.

Latest Patents

Fauve's latest patents include innovative compounds that have potential therapeutic applications. One of his notable inventions is the glycosylphospholipid nucleoside derivatives, which are based on a specific formula involving nucleoside derivatives such as 3'-azidothymidine (AZT), 2', 3'-dideoxythymidine (ddT), and 2'-deoxy-5-fluorouridine (dFU). Another significant patent involves phosphorylated 3-glyceryl-esters of glucose, which relates to a drug active against infections. This drug contains an active principle formed of an ose or polyose product that bears at least one phosphorylated function and at least one diacylated 3-glyceryl-ester function.

Career Highlights

Fauve is associated with the prestigious Institut Pasteur, where he conducts his research and development work. His career has been marked by a commitment to advancing pharmaceutical science and improving therapeutic options for various infections.

Collaborations

Throughout his career, Fauve has collaborated with esteemed colleagues such as Tam Huynh Dinh and Catherine Gouyette. These collaborations have further enriched his research and contributed to the success of his innovative projects.

Conclusion

Robert M Fauve's contributions to the field of pharmaceuticals through his patents and research at Institut Pasteur highlight his role as a significant inventor. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in medicine.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]